Equations (14)–(15) — unique outcome-based best response
ProvedRareDisease.Endogenous.best_response_Bbest-responseoutcome-based-paymentp2o-batch-pfp2ap2o-gran-per-chapterp2o-plan-paperp2o-v1subsidy
Let and . In Setting (1B), where the manufacturer chooses price and target efficacy but is paid only when treatment succeeds, its complete best-response set is
The price differs from Setting (1A), while target efficacy is the same at a fixed policy.
Formalization Note The text preceding (14) cites equation (9), which describes consortium pricing; the manufacturer-pricing objective here is equation (8). The manufacturer chooses and , without an upper bound on .
Preamble
import Mathlib import Definitions.Def_RareDisease_Endogenous_Setting
Formal statement
namespace RareDisease.Endogenous
/-- Equations (14)–(15), p. 13: the joint outcome-based best response is unique. -/
theorem best_response_B (k α β : ℝ) (hk : 0 < k) (hpolicy : IsPolicy α β) :
BRB k α β = {
(1 / (2 * (1 - β)),
1 / (8 * (1 - α) * k * (1 - β)))} := by sorry
end RareDisease.Endogenous
Source
Olsder, Martagan, Tang, Improving Access to Rare Disease Treatments: Optimal Subsidies, Pricing, and Payment, SSRN working paper 3481150 (version of 2019-11-13), p. 13, §4.2, equations (14)–(15)
Human review
Confirmed by the mission captain (proposal self-audit).
Confirmed by the moderator at approval.